tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000078003 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
HCAMRKABBVBMYPFEABT
NYSE Health care · Pharmaceuticals

Pfizer PFE

PFE quote by TradingView

Pfizer Inc. is a research-based, global biopharmaceutical company. 10-K, Item 1

Employees
75,000
Headquarters
New York, NY
CEO
Albert Bourla
Next results
around Feb 2, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $62.6B through the costs to a net profit of $7.8B · income statement of the 10-K

12% net margin
Revenue to Gross profit: $46.5BRevenue to Cost of revenue: $16.1BGross profit to Net profit: $7.8BGross profit to Costs, tax, other: $38.7B Revenue: $62.6B REVENUE $62.6B −2% Y/Y Gross profit: $46.5B · 74% margin GROSS PROFIT $46.5B 74% margin Cost of revenue: $16.1B · 26% of revenue COST OF REVENUE $16.1B 26% of revenue Net profit: $7.8B · 12% margin NET PROFIT $7.8B 12% margin · −3% Y/Y Costs, tax, other: $38.7B · 62% of revenue COSTS, TAX, OTHER $38.7B 62% of revenue
Gross profit $46.5B 74% margin
Net profit $7.8B 12% margin · −3% Y/Y
The full income statement, year by year

PFE among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: -1.6%, above 3% of 59 peers (their median 7.2%) REVENUE GROWTH -1.6% · above 3% Gross margin: 73.4%, above 80% of 50 peers (their median 64.2%) GROSS MARGIN 73.4% · above 80% Net margin: 6.3%, above 34% of 59 peers (their median 9.7%) NET MARGIN 6.3% · above 34% FCF margin: 18.5%, above 62% of 55 peers (their median 15.2%) FCF MARGIN 18.5% · above 62%
PFE Peer median Below the median

What changed

6 new risk paragraphs. 10-K filed Feb 26, 2026 against Feb 27, 2025.

Risk factors
6 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
3 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +3.6% vs revenue -1.6% (+5.2 pts)
  • Cash from operations $11.7B vs net income $7.8B (FY ending Dec 31, 2025)
  • Inventory -1.8% vs revenue -1.6% (-0.2 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Evaluation of the U.S. Medicare, Medicaid, and performance-based contract rebates accrual; Evaluation of gross unrecognized tax benefits
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

6 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 6 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Some payers are directing beneficiaries to third-party patient assistance programs, rather than covering certain treatments. In other instances, insurers disallow manufacturers’ co-pay assistance from counting toward reaching the deductible or out-of-pocket maximum. Both approaches can delay access to treatment or result in treatment…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Several manufacturers, including Pfizer, have signed voluntary agreements with the Trump Administration designed to ensure U.S. patients pay lower prices for their prescription medicines. This may impact the competitive environment, including pricing dynamics for any of our current or potential future products, as well as contracting…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    In the U.S., pharmaceutical product pricing is subject to government and public scrutiny and calls for reform, and, as a result, many of our products are subject to increasing pricing pressures. We expect to see continued focus by the U.S. government on regulating pricing and access to medicine. For example, in May and July 2025, the…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$101.2B$59.6B$63.6B$62.6B
Net income$31.4B$2.1B$8.0B$7.8B
Operating cash flow$29.3B$8.7B$12.7B$11.7B
Free cash flow$26.0B$4.8B$9.8B$9.1B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$62.6B ▼ 1.6% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings
  • OfficerNov 3, 2026
    CFO change (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”).
  • 8-KNov 3, 2026
    Quarterly results 8-K item 2.02
  • 10-QNov 3, 2026
    Quarterly report (10-Q) period ended Sep 27, 2026

About the company

Pfizer, New York, NY · from the 10-K filed Feb 26, 2026

Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Headquarters
New York, NY
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 3, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we employed approximately 75,000 people worldwide" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PFE/export.csv") into a cell.